A novel minimal model to describe NEFA kinetics following an intravenous glucose challenge.
Dynamics of nonesterified fatty acid (NEFA) metabolism in humans requires quantification if we are to understand the etiology of such diseases as type 1 and 2 diabetes, as well as metabolic syndrome and obesity, or if we are to elucidate the mechanism of action of various interventions. We present a new compartmental model that employs the pattern of plasma glucose concentrations in healthy young adults to predict dynamic changes that occur in plasma NEFA concentrations during either a glucose-only intravenous glucose tolerance test, or an insulin-modified intravenous tolerance test, or a modified protocol during which variable-rate glucose infusions were administered to prevent plasma glucose from declining below 100 mg/dl. The model described all of the major features of NEFA response to an intravenous glucose tolerance test, including an initial latency phase, a phase during which plasma NEFA concentrations plummet to a nadir, and a rebound phase during which plasma NEFA concentrations may rise to a plateau concentration, which may be substantially higher than the initial basal NEFA concentration. This model is consistent with physiological processes and provides seven adjustable parameters that can be used to quantify NEFA production (lipolysis) and utilization (oxidation). When tested on data from the scientific literature, the range in estimated rate of lipolysis was 24-36 micromol.l(-1).min(-1) and for NEFA oxidation rate was 25-54 micromol.l(-1).min(-1). All model parameters were well identified and had coefficients of variation < 15% of their estimated values. It is concluded that this model is suitable to describe NEFA kinetics in human subjects.
Boston
Ray C
RC
School of Veterinary Medicine, University of Pennsylvania, Kennett Square, Pennsylvania 19348, USA. drrayboston@yahoo.com
Moate
Peter J
PJ
D000328:Adult; D001786:Blood Glucose / Q000378:metabolism*; D005230:Fatty Acids, Nonesterified / Q000097:blood / Q000378:metabolism*; D005947:Glucose / Q000008:administration & dosage*; D005951:Glucose Tolerance Test / Q000379:methods; D006801:Humans; D007262:Infusions, Intravenous; D007700:Kinetics; D008066:Lipolysis; D008954:Models, Biological; D010084:Oxidation-Reduction; D012016:Reference Values; D015203:Reproducibility of Results
D001786:Blood Glucose; D005230:Fatty Acids, Nonesterified; D005947:Glucose